Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Combination Study for High Risk Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT03104270
- Locations
- 🇺🇸
Robert A. Moss, MD, FACP, Inc, Fountain Valley, California, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
🇺🇸California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT03030261
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado, United States
🇨🇦University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 6
- Registration Number
- NCT03023527
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
🇪🇸ICO Badalona, Badalona, Spain
🇪🇸Hospital Ramón y Cajal, Madrid, Spain
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 307
- Registration Number
- NCT02990338
- Locations
- 🇨🇿
Investigational Site Number : 2030001, Olomouc, Czechia
🇨🇿Investigational Site Number : 2030004, Hradec Kralove, Czechia
🇵🇱Investigational Site Number : 6160005, Krakow, Malopolskie, Poland
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT02939183
- Locations
- 🇪🇸
Research Site, Pamplona, Navarra, Spain
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 73
- Registration Number
- NCT02916420
- Locations
- 🇨🇳
Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 37
- Registration Number
- NCT02807454
- Locations
- 🇺🇸
UCLA Division of Hematology Oncology, Los Angeles, California, United States
🇨🇦Local Institution - 103, Saint John, New Brunswick, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 170
- Registration Number
- NCT02726581
- Locations
- 🇺🇸
Local Institution - 0035, Chicago, Illinois, United States
🇸🇪Local Institution - 0064, Huddinge, Sweden
🇺🇸Local Institution - 0016, Fountain Valley, California, United States
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
- Conditions
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 67
- Registration Number
- NCT02719613
- Locations
- 🇺🇸
Local Institution - 0009, Atlanta, Georgia, United States
🇺🇸Local Institution - 0002, Boston, Massachusetts, United States
🇯🇵Local Institution - 0048, Koto-ku, Tokyo, Japan
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT02718833
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Newton-Wellesley Hospital, Newton, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.